文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

高龄患者使用聚苯乙烯磺酸钠与严重不良胃肠道事件住院风险的相关性

Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age.
PubMed 文献 · JAMA Intern Med · 2019-01-01
一句话结论在≥66岁门诊患者中,使用聚苯乙烯磺酸钠与30天内严重不良胃肠道事件住院或急诊就诊风险升高相关(HR 1.94,95%CI 1.10-3.41),作者建议谨慎使用。

该研究为基于人群的回顾性匹配队列研究,纳入加拿大安大略省2003年4月1日至2015年9月30日期间≥66岁、门诊配发聚苯乙烯磺酸钠的成人,随访至2016年3月31日。共27 704人配发该药,其中20 020人与20 020名非使用者经高维倾向评分匹配。使用聚苯乙烯磺酸钠与30天内不良胃肠道事件复合终点(肠道缺血/血栓形成、胃肠道溃疡/穿孔或切除/造瘘的住院或急诊就诊)风险升高相关(37例[0.2%],发生率22.97/1000人年 vs 18例[0.1%],发生率11.01/1000人年;HR 1.94,95%CI 1.10-3.41)。在基线有估算肾小球滤过率和血清钾值的亚组中结果一致(HR 2.91,95%CI 1.38-6.12),肠道缺血/血栓形成是最常见的不良胃肠道事件类型。作者结论认为该关联需进一步确认,并建议对持续使用聚苯乙烯磺酸钠持谨慎态度。

要点

  • 在≥66岁门诊患者中,配发聚苯乙烯磺酸钠者30天内不良胃肠道事件复合终点发生37例(0.2%),非使用者18例(0.1%)。
  • 使用聚苯乙烯磺酸钠与30天内不良胃肠道事件风险升高相关(HR 1.94,95%CI 1.10-3.41)。
  • 在基线有估算肾小球滤过率和血清钾值的亚组中,关联一致(HR 2.91,95%CI 1.38-6.12)。
  • 肠道缺血/血栓形成是使用聚苯乙烯磺酸钠后最常见的不良胃肠道事件类型。
  • 作者结论认为该发现需进一步确认,并建议对持续使用聚苯乙烯磺酸钠持谨慎态度。

适用人群与场景

  • 加拿大安大略省≥66岁成人,2003年4月1日至2015年9月30日期间在门诊配发聚苯乙烯磺酸钠者,随访至2016年3月31日。

研究设计与关键结果

  • 研究类型为基于人群的回顾性匹配队列研究;从1 853 866名合格成人中,27 704人配发聚苯乙烯磺酸钠(平均[SD]年龄78.5[7.7]岁;54.7%男性),20 020名使用者与20 020名非使用者经高维倾向评分匹配。
  • 主要终点为首次配发聚苯乙烯磺酸钠后30天内不良胃肠道事件复合终点(肠道缺血/血栓形成、胃肠道溃疡/穿孔或切除/造瘘的住院或急诊就诊)。
  • 使用聚苯乙烯磺酸钠 vs 非使用者:37例(0.2%),发生率22.97/1000人年 vs 18例(0.1%),发生率11.01/1000人年;HR 1.94(95%CI 1.10-3.41)。
  • 在基线有估算肾小球滤过率和血清钾值的亚组中,HR 2.91(95%CI 1.38-6.12)。
  • 肠道缺血/血栓形成是最常见的不良胃肠道事件类型。

证据类型、等级与局限

  • 证据类型:基于人群的回顾性匹配队列研究。
  • 作者结论:使用聚苯乙烯磺酸钠与严重不良胃肠道事件住院风险升高相关;这些发现需进一步确认,并建议对持续使用聚苯乙烯磺酸钠持谨慎态度。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,聚苯乙烯磺酸钠的使用与严重不良胃肠道事件住院风险升高相关,这些发现需进一步确认,并建议对持续使用聚苯乙烯磺酸钠持谨慎态度。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sodium polystyrene sulfonate is commonly prescribed for the treatment of hyperkalemia. Case reports of intestinal injury after administration of sodium polystyrene sulfonate with sorbitol resulted in a US Food and Drug Administration warning and discontinuation of combined 70% sorbitol-sodium polystyrene sulfonate formulations. There are ongoing concerns about the gastrointestinal (GI) safety of sodium polystyrene sulfonate use.

OBJECTIVE: To assess the risk of hospitalization for adverse GI events associated with sodium polystyrene sulfonate use in patients of advanced age.

DESIGN, SETTING, AND PARTICIPANTS: Population-based, retrospective matched cohort study of eligible adults of advanced age (≥66 years) dispensed sodium polystyrene sulfonate from April 1, 2003, to September 30, 2015, in Ontario, Canada, with maximum follow-up to March 31, 2016. Initial data analysis was conducted from August 1, 2018, to October 3, 2018; revision analysis was conducted from February 25, 2019, to April 2, 2019. Cox proportional hazards regression models were used to examine the association of sodium polystyrene sulfonate use with a composite of GI adverse events compared with nonuse that was matched via a high-dimensional propensity score. Additional analyses were limited to a subpopulation with baseline laboratory values of estimated glomerular filtration rate and serum potassium level.

EXPOSURE: Dispensed sodium polystyrene sulfonate in an outpatient setting.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of adverse GI events (hospitalization or emergency department visit with intestinal ischemia/thrombosis, GI ulceration/perforation, or resection/ostomy) within 30 days of initial sodium polystyrene sulfonate prescription.

RESULTS: From a total of 1 853 866 eligible adults, 27 704 individuals were dispensed sodium polystyrene sulfonate (mean [SD] age, 78.5 [7.7] years; 54.7% male), and 20 020 sodium polystyrene sulfonate users were matched to 20 020 nonusers. Sodium polystyrene sulfonate use compared with nonuse was associated with a higher risk of an adverse GI event over the following 30 days (37 events [0.2%]; incidence rate, 22.97 per 1000 person-years vs 18 events [0.1%]; incidence rate, 11.01 per 1000 person-years) (hazard ratio, 1.94; 95% CI, 1.10-3.41). Results were consistent in additional analyses, including the subpopulation with baseline laboratory values (hazard ratio, 2.91; 95% CI, 1.38-6.12), and intestinal ischemia/thrombosis was the most common type of GI injury.

CONCLUSIONS AND RELEVANCE: The use of sodium polystyrene sulfonate is associated with a higher risk of hospitalization for serious adverse GI events. These findings require confirmation and suggest caution with the ongoing use of sodium polystyrene sulfonate.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Noel JA, Bota SE, Petrcich W, et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. JAMA Intern Med. 2019. PMID: 31180477. doi:10.1001/jamainternmed.2019.0631

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。